News | August 14, 2012

Beaumont-led and Blue Cross-sponsored initiative enhances CT heart testing quality and value


August 14, 2012 — A study led by Kavitha Chinnaiyan, M.D., director of advanced cardiac imaging education, Beaumont Health System (Mich.), has shown that inappropriate CCTA (coronary computed tomography [CT] angiography) use can be reduced by 60 percent with educational programs, increased physician collaboration and close monitoring. The research is published in the Aug. 8 online issue of the Journal of the American College of Cardiology (JACC).

The results come from a multicenter, statewide quality improvement initiative called the Advanced Cardiovascular Imaging Consortium (ACIC), sponsored by Blue Cross Blue Shield/Blue Care Network of Michigan. A total of 47 centers in Michigan took part in the ongoing initiative from July 2007 to December 2010.

"We looked at more than 25,000 patients in the ACIC registry, reviewed data on appropriate use, then had a period of intervention with 5,000 referring physicians across the state offering educational programs, close monitoring and feedback to physicians on CT use," said Chinnaiyan, ACIC program director.

Coronary CT angiography is the fastest growing application of CT scanners in the United States. About 500,000 Americans undergo CCTA each year at an average cost of $500 to $1,500. As it is a relatively new imaging methodology, the statewide collaborative was formed in part to assess how providers should best utilize the technology, while at the same time reducing inappropriate use. After the intervention, there was a follow-up period where appropriate use was reviewed again. It was found that appropriate use increased and inappropriate use decreased by 60 percent across all referring physician specialties, including cardiologists, internists and emergency room physicians.

"The study suggests that voluntary, mutually established quality metrics reinforced by education and feedback can result in major changes in inappropriate use," said Chinnaiyan. "This collaborative approach involving physicians, hospitals and payers may be applied beyond CCTA to enhance value in other areas of medicine."

Earlier this year, ACIC-generated research found that CCTA is more effective than cardiac stress testing at identifying heart disease requiring an expensive, invasive heart catheterization procedure. That research, also authored by Chinnaiyan, was published in the Feb. 14 issue of JACC.

For more information: www.beaumont.edu


Related Content

News | Cardiac Imaging

April 30, 2025 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has launched Viz ...

Time May 02, 2025
arrow
News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | SPECT Imaging

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing ...

Time December 05, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now